| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 797.86B | 753.23B | 679.32B | 709.37B | 606.68B | 492.73B |
| Gross Profit | 440.75B | 427.10B | 402.53B | 410.73B | 336.21B | 285.69B |
| EBITDA | 263.98B | 260.18B | 253.73B | 255.74B | 204.94B | 169.58B |
| Net Income | 348.99B | 347.47B | 204.59B | 191.92B | 152.43B | 131.61B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 880.91B | 918.26B | 858.83B | 772.60B | 738.19B |
| Cash, Cash Equivalents and Short-Term Investments | 204.87B | 203.00B | 198.93B | 218.74B | 166.94B | 192.96B |
| Total Debt | 0.00 | 2.85B | 3.03B | 3.06B | 2.50B | 2.71B |
| Total Liabilities | -703.98B | 176.93B | 169.36B | 163.44B | 144.38B | 131.25B |
| Stockholders Equity | 703.98B | 700.30B | 745.07B | 691.55B | 624.56B | 603.47B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 153.48B | 136.16B | 161.35B | 136.34B | 106.90B |
| Operating Cash Flow | 0.00 | 176.27B | 171.79B | 188.78B | 157.76B | 125.27B |
| Investing Cash Flow | 0.00 | -3.96B | 15.63B | -57.32B | -22.38B | 56.83B |
| Financing Cash Flow | 0.00 | -170.37B | -185.51B | -130.06B | -135.81B | -186.34B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹4.04T | 11.56 | ― | 3.52% | 4.55% | 70.17% | |
69 Neutral | ₹335.06B | 26.10 | ― | 1.29% | 24.53% | 39.08% | |
69 Neutral | ₹40.21B | 17.59 | ― | 3.93% | ― | ― | |
65 Neutral | ₹422.03B | 103.20 | ― | 0.62% | 8.08% | -22.42% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | ₹30.51B | 18.55 | ― | 0.54% | 9.83% | -0.92% | |
61 Neutral | ₹199.81B | 57.36 | ― | 0.61% | 10.61% | 7.97% |
ITC Limited has notified the stock exchanges that it has published newspaper advertisements regarding a tribunal-ordered hearing of a company petition on 6 February 2026 before the National Company Law Tribunal, Kolkata Bench. The petition seeks approval of a proposed Scheme of Amalgamation under the Companies Act, 2013, involving the merger of Sresta Natural Bioproducts Private Limited and Wimco Limited into ITC Limited, a move that, once sanctioned, is expected to consolidate these businesses within ITC’s corporate structure and potentially streamline operations and integration of acquired entities.
ITC Limited announced the successful passing of resolutions through a postal ballot for the appointment of Mr. Amitabh Kant as an Independent Director and the re-appointment of Mr. Hemant Malik as a Wholetime Director. This decision reflects ITC’s strategic focus on strengthening its leadership team to enhance governance and drive future growth.
ITC Limited has announced changes in its board of directors, with the appointment of Mr. Amitabh Kant as an Independent Director for five years starting January 2026, and the re-appointment of Mr. Hemant Malik as a Wholetime Director for two years starting August 2026. These appointments, approved by the company’s members through e-voting, are expected to strengthen ITC’s leadership and strategic direction, potentially impacting its market positioning and stakeholder relations positively.